A closer look at YAE1 (C7orf36), a potential drug target and biomarker for cancer

Target Name: YAE1

NCBI ID: G57002

YAE1

A closer look at YAE1 (C7orf36), a potential drug target and biomarker for cancer

The search for new cancer treatments and biomarkers has led to the identification of a growing number of promising candidates. One of these candidates is YAE1 (C7orf36), a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. In recent years, researchers have been investigating the potential implications of YAE1 as a drug target and biomarker for cancer. In this article, we will take a closer look at YAE1, its functions, and its potential as a cancer drug.

What is YAE1?

YAE1 is a non-coding RNA molecule that was identified by researchers in 2012. It is characterized by a unique N-terminus that consists of a 23- amino acid protein called YAP-TKG, which is responsible for its unique structure and function. YAE1 is expressed in various tissues and cells of the body, including the brain, heart, liver, and cervical cancer cells.

YAE1's functions

YAE1 has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to regulate the activities of several proteins, including the transcription factor NF-kappa-B and the tyrosine kinase Src. YAE1 has also been shown to play a role in the development and progression of cancer, by promoting the growth and survival of cancer cells.

As a drug target, YAE1 has the potential to be a target for small molecules that can inhibit its functions and disrupt its signaling pathways. This could lead to the development of new treatments for various types of cancer.

As a biomarker, YAE1 has the potential to be used as a diagnostic or predictive marker for cancer. Studies have shown that YAE1 levels are significantly elevated in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that YAE1 may be a useful biomarker for cancer diagnosis and monitoring.

YAE1's potential as a drug target

The potential of YAE1 as a drug target is based on its unique structure and functions. YAE1 has been shown to interact with several proteins, including the transcription factor NF-kappa-B and the tyrosine kinase Src. This suggests that it may be a useful target for small molecules that can inhibit its signaling pathways.

One potential approach to blocking YAE1's functions is to develop small molecules that can inhibit the activity of YAP-TKG, the protein that functions as the N-terminus of YAE1. This could lead to the development of new treatments for various types of cancer.

Another potential approach to blocking YAE1's functions is to target its interactions with other proteins. YAE1 has been shown to interact with several proteins, including the transcription factor NF-kappa-B and the tyrosine kinase Src. Developing small molecules that can inhibit these interactions may be a promising approach to blocking YAE1's functions.

YAE1's potential as a biomarker

YAE1 has also been shown to play a critical role in the development and progression of cancer. Its expression is significantly elevated in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that YAE1 may be a useful biomarker for cancer diagnosis and monitoring.

One potential approach to using YAE1 as a biomarker is to develop small molecules that can inhibit its expression in cancer cells. This could lead to the development of new treatments for various types of cancer.

Another potential approach to using YAE1 as a biomarker is to use it as a diagnostic tool. Researchers have shown that YAE1 levels are significantly elevated in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that Y

Protein Name: YAE1 Maturation Factor Of ABCE1

Functions: The complex LTO1:YAE1 functions as a target specific adapter that probably recruits apo-ABCE1 to the cytosolic iron-sulfur protein assembly (CIA) complex machinery (PubMed:26182403). May be required for biogenesis of the large ribosomal subunit and initiation of translation (PubMed:26182403)

The "YAE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YAE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets